An expansion of glutamines within the human ataxin-1 protein underlies spinocerebellar ataxia type 1 (SCA1), a dominantly inherited neurodegenerative disorder characterized by ataxia and loss of cerebellar Purkinje neurons. Although the mechanisms linking the mutation to the disease remain unclear, evidence indicates that it involves a combination of both gain and loss of functions of ataxin-1. We previously showed that the mutant ataxin-1 interacts with Anp32a, a potent and selective PP2A inhibitor, suggesting a role of PP2A in SCA1. Herein, we found a new function of ataxin-1: the modulation of Pp2a activity and the regulation of its holoenzyme composition, with the polyglutamine mutation within Atxn1 altering this function in the SCA1 mouse cerebellum before disease onset. We show that ataxin-1 enhances Pp2a-bb expression and down-regulates Anp32a levels without affecting post-translational modifications of Pp2a catalytic subunit (Pp2a-c) known to regulate Pp2a activity. In contrast, mutant Atxn1 induces a decrease in Y307-phosphorylation in Pp2a-c, known to enhance its activity, while reducing Pp2a-b expression and inhibiting Anp32a levels. qRT -PCR and chromatin immunoprecipitation analyses show that ataxin-1-mediated regulations of the Pp2a-bb subunit, specifically bb2, and of Anp32a occur at the transcriptional level. The Pp2a pathway alterations were confirmed by identified phosphorylation changes of the known Pp2a-substrates, Erk2 and Gsk3b. Similarly, mutant ataxin-1-expressing SH-SY5Y cells exhibit abnormal neuritic morphology, decreased levels of both PP2A-Bb and ANP32A, and PP2A pathway alterations, all of which are ameliorated by overexpressing ANP32A. Our results point to dysregulation of this newly assigned function of ataxin-1 in SCA1 uncovering new potential targets for therapy.
INTRODUCTION
Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited rare disorder caused by an expansion of glutamines within the ataxin-1 (ATXN1) protein (1) . SCA1 is a fatal progressive neurodegenerative disease of late onset characterized by cerebellar ataxia accompanied by varying degrees of oculomotor deficits, pyramidal and extrapyramidal signs and peripheral neuropathy (2) . The primary neurodegeneration in SCA1 patients and animal models is observed in Purkinje cells (PCs) and dentate nucleus neurons in the cerebellum, with pathological loss of cerebellar PC dendrites, reduced dendritic trees, decreased formation of proximal spines, abnormal variable accumulation of neurofilaments and early formation of axonal spheroids (3, 4) . Although several molecular pathways affected in SCA1 are shared with other polyglutaminopathies, including other ataxias (5 -7), the events responsible for the early pathogenic changes in SCA1 remain unclear. Transcriptional dysregulation has been proposed as a primary and early mechanism in SCA1 cerebellar pathogenesis. In fact, several important pathways * To whom correspondence should be addressed at: Health Sciences Research Institute Germans Trias i Pujol (IGTP), Ctra. de Can Ruti, Camí de les Escoles s/n, Badalona, Barcelona, Spain. Tel: +34 934978687; Fax: +34 934978654; Email: amatilla@igtp.cat; amatilla@btnunit.org implicating glutamate, drd2, notch and wnt signalling have been shown transcriptionally dysregulated in the SCA1 mouse model (8 -10) . Recent data have shown that although SCA1 is mainly caused by a gain of function of mutant ataxin-1, dysregulation of normal ataxin-1 functions, particularly its role in transcription, modulate SCA1 pathogenesis (11) . This could be explained by the fact that the presence of the expanded polyglutamine induces opposite effects in Atxn1 protein interactions. Whereas its interactions with Sp1 and Capicua are shown to diminish (9, 12) , binding to RBM17 and ANP32A appear enhanced (13, 14) . The mutation may then confer Atxn1 the ability to both activate and repress gene expression by altering the biological functions of the interacting proteins.
In addition to forming part of the INHAT complex by which it exerts repression of gene transcription, Anp32a, also known as Lanp/PHAPI/I1PP2A/pp32/mapmodulin (15) , is a selective endogenous inhibitor of the protein phosphatase 2 (Pp2a) by binding its catalytic subunit (16) . Anp32a is highly expressed in the brain regions predominantly affected in SCA1 including the motor cortex, brainstem and cerebellum (15) . Anp32a appears to mediate neurite formation by its INHAT function and actively translocates to the cytoplasm during neuronal differentiation to mediate neurite growth through cytoskeleton regulation (15, 17, 18) . We and others previously showed that ANP32A interacts with ATXN1, with stronger affinity towards the mutant form (14, 19) . This led us to propose that alterations of ANP32A biological functions, including PP2A activity inhibition, could be dysregulated by the polyglutamine-expanded mutation within ATXN1 during the pathogenesis process in SCA1 (14) . However, this hypothesis or the functional consequences of the interaction and the possible underlying mechanisms have not been explored. The heterotrimeric PP2A is a ubiquitous and conserved serine/threonine phosphatase with broad substrate specificity as it regulates a myriad of cellular functions including transcription, translation, cell cycle, signal transduction, metabolism, cell growth and apoptosis (20) . Among the direct and indirect targets of PP2A are proteins in oncogenic signalling cascades, such as Raf and MEK, and in other signalling pathways such as AKT, beta-catenin, ERK and GSK3b. PP2A is highly regulated at the developmental, transcriptional and post-translational levels through the availability of the different subunits (21, 22) . The core enzyme consists of a catalytic (C) 36 kDa and scaffold structural (A) 65 kDa subunits which form a heterotrimeric holoenzyme upon binding to a regulatory B subunit. The scaffold (A) subunit (a or b), the catalytic (C) subunit isoforms (a or b) and the four regulatory (B) subunits families described to date, B (B55/PR55), B ′ (B56/PR61), B ′′ (PR72, PR130, PR59/ PR48), B ′′′ (PR93/SG2NA/PR110/striatin), with B and B ′ being the most abundant regulatory subunits in the brain, each consist of two to seven isoforms not including splice variants, alternate translation products, post-translational modifications and other protein and chemical modifiers (20) . All of these combine to yield a large number, at least 70, of highly diverse PP2A holoenzyme subtypes. The combination of the distinct catalytic-structural subunit isoforms dictates the regulatory subunit which will bind to form the holoenzyme and in turn the bound regulatory subunit appears to define the cellular and subcellular localizations of PP2A thereby narrowing its target specificity (23) . Post-translational modifications, such as the methylation of residue L309 and phosphorylation at Y307 in the catalytic subunit, regulate its binding to the regulatory subunits, with the binding to B subunits being selectively inhibited by increasing levels of phospho-Y307 and decreased L309 methylation (22, 24) . The regulatory subunits Bb, Bg, Ba, B ′ b and B ′ d are highly expressed in the cerebellum, with Bb being restricted to PCs (25) . Fine regulation of the Bb subunit appears critical for normal functioning of the cerebellar cortex, since a mutation consisting of an expanded CAG repeat in the Bb promoter region underlies spinocerebellar ataxia type 12 (SCA12) characterized by cerebellar atrophy and PC dysfunction (26) . Although the effect of the SCA12 mutation on Bb subunit expression levels in patients is not yet clear, in vitro data show up-regulation of expression driven by the PPP2R2B promoter with expanded CAG repeats (27) . Recent evidence shows that Bb consists of two isoforms with both being found in the cytoplasm, and Bb2 becoming recruited to the mitochondria during different stimuli including stress, to regulate mitochondria fusion -fission balance through dephosphorylation of Drp1 (28) . Furthermore, regulatory subunits B and B ′ have been shown to regulate Erk2 and GSK3b activity and to modulate neurite extension (29) (30) (31) (32) (33) . Interestingly, the activity of the PP2A-B ′ d holoenzyme was found modulated by dopamine signalling through the PKA phosphorylation of B ′ d (34). Although our work and that from other laboratories previously indicated that dopamine signalling, specifically through Drd2, is most likely altered in SCA1 (9, 35) , it remains undetermined whether the PP2A-B ′ d is altered in SCA1. Our previous studies describing the interaction between ATXN1 and ANP32A suggested a possible involvement of PP2A in SCA1 (14) . However, the effect of this interaction on the activation state of Pp2a and its mediated signalling pathways in the SCA1 mice have not been investigated. In addition, recent studies show that ATXN1, specifically the S776 phosphosite associated with ATXN1 toxicity, is a substrate of PP2A in the nucleus and that this phosphosite appears protected in the cytoplasm from dephosphorylation by the ATXN1 interaction with 14-3-3 protein (36) (37) (38) . Taken together these studies suggested a role for PP2A in SCA1 pathogenesis.
Thus, here we sought to determine the effects of Atxn1 and its mutation on Pp2a activity in the SCA1 mouse cerebellum. Unexpectedly, we found that ataxin-1 modulates Pp2a activity by transcriptionally regulating the Pp2a holoenzyme components bb2 and its endogenous inhibitor, Anp32a. In addition, we show that Atxn1, previously shown to activate the expression of Drd2 (9) , regulates the activation inducing phosphorylation of b ′ d at S566. Furthermore, we found that the polyglutamineexpanded mutation within Atxn1 modulates these regulatory functions. Pp2a pathway dysregulation was confirmed by identified phosphorylation changes of the known Pp2a-substrates Erk2 and Gsk3b in the SCA1 mouse cerebellum before disease onset. Similarly, mutant ATXN1-expressing SH-SY5Y cells exhibit abnormal neuritic morphology, decreased levels of both PP2A-Bb and ANP32A, and PP2A pathway alterations which are shown ameliorated by overexpressing ANP32A. Our results point to dysregulation of this newly assigned function of ataxin-1 in SCA1 and suggest new potential targets for therapy.
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RESULTS

Ataxin-1 regulates Pp2a activity and the polyglutamine-expansion mutation enhances this function
To determine whether Pp2a activity was regulated by Atxn1 expression, we immunoprecipitated Pp2a from cytosolic extracts of the cerebellum of 5-week-old Atxn1 knock-out (KO) and wild-type (WT) mice (Supplementary Material, Fig. S1A and B). We found that the Pp2a specific activity was significantly decreased in the Atxn1 KO mice (30%) compared with WT mice (F (1,6) ¼ 26.607, P ¼ 0.002) (Fig. 1A) . We then asked whether ATXN1 levels beyond those in wild-type mice could modulate Pp2a activity and measured the Pp2a activity in the cerebellum of 5-week-old ATXN1 overexpressing transgenic mice, A02. One-way ANOVA and the Tukey HSD post hoc test revealed that the Pp2a-specific activity was increased by 59% in the cerebellum of the wild-type ATXN1 overexpressing mice A02 compared with WT mice (F (2,11) ¼ 17.794; Tukey HSD: WT versus A02, P ¼ 0.027) (Fig. 1A) . We then sought to determine the effect of the mutant ATXN1 by measuring the Pp2a activity from cytoplasmic lysates of the same age, 5-week-old SCA1 transgenic mouse model, B05 well before it presents the ataxic phenotype. Interestingly, we found that the Pp2a activity was substantially higher (238%) in the mutant ATXN1 overexpressing SCA1 mice B05 compared with wildtype mice, and significantly higher than in the wild-type ATXN1 overexpressing mice A02 (Tukey HSD: B05 versus WT, P , 0.001; B05 versus A02, P ¼ 0.032) (Fig. 1A) . This dysregulation in Pp2a activity was also detected in the cerebellum of the B05 mice at 12 weeks of age when the mice are exhibiting the ataxic phenotype (F (2, 8) (Fig. 1B) . These data suggest that the increased Pp2a activity in the SCA1 B05 mice may, at least in part, be due to decreased levels of phospho-Y307 Pp2a-c since it allows a wider range of regulatory binding to the core Pp2a enzyme (23) .
Ataxin-1 enhances Pp2a-b and represses Anp32a expression in the mouse cerebellum
We further assessed the levels of the regulatory subunits and found that in the cerebellum of mice lacking Atxn1 there was a significant decrease (30%) in Pp2a-b subunit protein compared with WT mice (F (1,6) ¼ 9.629, P ¼ 0.021). On the other hand, Pp2a-b subunit protein levels in mice overexpressing ATXN1 (A02) increased (23%) while they remained unchanged in the mutant ATXN1 overexpressing mice (B05) relative to WT mice (F (2,12) ¼ 6.699, P ¼ 0.013, Tukey HSD: WT versus A02, P ¼ 0.019; WT versus B05, P ¼ 1.00; A02 versus B05, P ¼ 0.023) ( Fig. 1C and D) . Furthermore, of all three isoforms of Pp2a-b identified in the cerebellum (a, b and g) only Pp2a-bb, known to be highly expressed in cerebellar PCs (25) , appeared regulated by Atxn1 as it was significantly altered in the Atxn1 KO mice (Fig. 1E ) (Pp2a-bb:
These data indicate that Atxn1 regulates the Pp2a-b levels in the mouse cerebellum and that the polyglutamine-expanded mutation appears to interfere with this function of ataxin-1. We then examined the possible role of the endogenous inhibitor of Pp2a, Anp32a, in the Atxn1-mediated modulation of Pp2a activity. We assessed the levels of Anp32a in the cerebellum of the Atxn1 KO and Atxn1 overexpressing transgenic mice. We detected approximately a 3-fold increase in Anp32a levels in the Atxn1 KO compared with WT mice (F (1,6) ¼ 8.262, P ¼ 0.043) (Fig. 1F) . These data point to a role of Atxn1 in the regulation of Anp32a, specifically, it suggests that Atxn1 suppresses Anp32a expression. This was further supported by the finding that when wild-type (A02) or mutant (B05) ATXN1 was overexpressed in the cerebellum there was a 4-and 2-fold decrease in Anp32a levels, respectively (F (2,12) ¼ 6.560, P ¼ 0.011; Tukey HSD: WT versus A02, P ¼ 0.012; WT versus B05, P ¼ 0.042) (Fig. 1F ). Taken together these data suggest that while the expression of WT, but not the mutant ATXN1, induces Pp2a-bb, both WT and mutant ATXN1 down-regulate Anp32a levels. Interestingly, analysis of the cerebellum of Atxn1 heterozygous (+/2) mice, which have one copy of the endogenous Atxn1 gene, shows WT levels of Anp32a (WT versus Atxn1 heterozygous: Fig. S2 ). However, one copy of the Atxn1 gene does not appear sufficient to achieve the same levels as those in WT mice for Pp2a-bb (WT versus Atxn1 heterozygous: Fig. S2 ).
We then asked whether transcriptional regulation underlies the Pp2a-bb and Anp32a protein level changes. For these experiments, we examined the Pp2a-bb and Anp32a mRNA levels from the cerebellum of the WT and Atxn1 KO mice. qRT -PCR analysis indicates that Atxn1 regulates Pp2a-bb, specifically isoform 2, and Anp32a protein levels in the 5-week-old mouse cerebellum at the transcriptional level ( Fig. 2A ) (Ppp2r2b2:
These changes were not observed in either the striatum (Ppp2r2b2: F (1,10) ¼ 3.297, P ¼ 0.099; Anp32a: These data also support a role of the mutation in the interference of the wild-type ATXN1 function in inducing Pp2a-bb expression (Fig. 2C) . Furthermore, as revealed by the ChIP analysis of the Atxn1 WT and KO mice, ATXN1was also found to occupy the PPP2R2B and ANP32A promoters in the differentiated SH-SY5Y cell culture system (Fig. 2D) . Interestingly, in both mice and the human cells there appears to be proportionately less mutant ATXN1 bound to the promoter regions analysed, although there are equal levels of the WT and mutant ATXN1 in the nuclear fractions (F (1, 4) Fig. S4 ). Ongoing studies aim to understand the mechanisms underlying the differential transcriptional regulation from the Pp2a-bb and Anp32a promoters by Atxn1.
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The Pp2a holoenzyme composition and signalling are altered in the cerebellum of SCA1 mice
To determine whether the identified Atxn1-mediated changes in Pp2a-b and Anp32a levels in the cerebellum were also reflected in the assembled Pp2a holoenzyme, we analysed Pp2a-a antibody immunoprecipitates from the WT, Atxn1 KO and the ATXN1 transgenic mice ( Fig. 3A and B). We found that the levels of the Pp2a-b regulatory subunit (WT versus KO: (Fig. 1C  and D) . Likewise, no differences were noted in Pp2a-b ′ d levels in Pp2a-a immunoprecipitates (WT versus KO: F (1,6) ¼ 0.056, P ¼ 0.821; WT versus A02 versus B05: F (1,6) ¼ 0.313, P ¼ 0.596) from any of the cerebellar samples we analysed ( Fig. 3A and B) . We then examined the proportion of the activating phosphosite Pp2a-b ′ d (S566), known to be regulated by Drd2 signalling through PKA (34) . Drd2 levels were previously reported decreased due to Atxn1 loss of function in the Atxn1 KO and in B05 SCA1 mice, and increased in the A02 mice (9) . In fact, we found that levels of phosphorylated Pp2a-b ′ d are highest in the cytoplasmic extracts of the cerebellum of the KO compared with their respective WT mice control (Fig. 3A -D) . This evidence supports our previous hypothesis that PKA signalling is dysregulated, as a consequence of the altered Drd2 levels, in both the Atxn1 KO and SCA1 B05 mice (9) . Furthermore, that the levels of Anp32a, the endogenous inhibitor of Pp2a which is bound to the Pp2a holoenzyme, are lower in mice overexpressing WT and mutant ATXN1 (A02 and B05, respectively), indicates that these have different subtypes of active Pp2a as defined by their bound regulatory subunits ( Fig. 3A and B) . Specifically, the data from these studies suggest that the Pp2a holoenzymes in the Atxn1 KO contain high levels of bound Anp32a, phospho-Pp2a-b ′ d, and phopho-Y307 Pp2a-c, and low Pp2a-bb levels. In mice, overexpressing wild-type ATXN1 it is composed of low Anp32a and phospho-Pp2a-b ′ d, and high Pp2a-bb and phopho-Y307 Pp2a-c. However, in the mutant ATXN1 overexpressing SCA1 mice (B05), the Pp2a holoenzymes appear to have low levels of Anp32a, Pp2a-bb phopho-Y307 Pp2a-c, and high levels of phospho-Pp2a-b ′ d. Very interestingly, the Pp2a holoenzymes in the cerebellum of the Atxn1 KO and the ATXN1 mutant overexpressing mice show similar proportions of both Pp2a-bb and phosphoPp2a-b ′ d, but differ in levels of the endogenous inhibitor, Anp32a and the B-subunit inhibitory phosphosite Y307 on Pp2a-c. We have now confirmed these Pp2a regulatory subunit level changes in SCA1 patient fibroblast samples (data not shown). Overall, these data indicate that Atxn1 modulates the levels and the composition of the Pp2a holoenzyme and, importantly, point to an Atxn1 mutation-mediated dysregulation of the targets and downstream signalling pathways regulated by Pp2a.
Pp2a is a known negative regulator of Erk2, which is also regulated by Anp32a, and is also a positive regulator of GSK3b 
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Human 29, 30, 39) . Therefore, we confirmed the functional effects of the Atxn1-mediated alterations in Pp2a activity and the modulation of its holoenzyme composition by identified changes in activating Erk phosphosites (Thr202/Tyr204) and in the activity inhibiting GSK3b serine-9 phosphorylation in the mouse cerebellum of the Atxn1 KO, A02, and B05 mice ( Fig. 3C and D) . Levels of phosphorylated Erk2 (pErk2) but not Erk1(pErk1) were higher in the cerebellum of the Atxn1 KO compared with WT mice which express Atxn1 (pErk2: These data show that both pErk2 and pGSK3b levels are increased in mice with lower than normal Pp2a activity as has been previously shown for pErk2 in the Pp2a activity-deficient L199P transgenic mice (29) . However, decreases in the phosphorylation levels of Erk2 and GSK3b, resulting in Erk2 inactivation and GSK3b activation, respectively, may be under a more stringent regulatory control. In fact, we detect decreases in Erk2 and GSK3b activity-modulating phosphosites only in the B05 cerebellum which shows a 238% increase in Pp2a activity compared with a 59% activity increase in the A02 over that in the WT mice. That levels of the GSK3b phosphorylated serine-9 are decreased in the B05, but not in the A02 mice cerebella indicates that this alteration is not caused by increments in the Atxn1 transgene levels, but rather that it is a result of acquired properties of the mutant Atxn1. Our results suggest that these acquired properties of the mutant ATXN1 may include its enhanced ability to suppress Anp32a expression, together with its inability to induce Pp2a-b expression, its induction of increased levels of active Pp2a-b ′ d, and its ability to bind b-type regulatory subunits (lower phospho-Y307 Pp2a-c).
ANP32A overexpression restores GSK3b ser9 phosphorylation and neurite morphology alterations induced by mutant ataxin-1
We then tested whether the expression of the endogenous PP2A inhibitor ANP32A in the SH-SY5Y expressing ATXN1 Fig. 3C and E; Supplementary Material, Fig. S5 ). This suggests that Anp32a is able to inhibit the Pp2a holoenzyme(s) involved in dephosphorylation of the ser9 phosphosite in GSK3b.
Because GSK3b has been previously shown to play a role in neurite extension and stability, and we found that the expression of the mutant ATXN1 altered the levels of the activitymodulating phosphosite ser-9 in GSK3b, we investigated whether the expression of ATXN1[80Q] in differentiated SH-SY5Y cells had any effect on neurite morphology, specifically neurite length and the presence of spines (Fig. 4 , Supplementary Material Fig. S6) (Fig. 4A -C) . These morphological changes did not appear to be caused by cell death as no changes in cell soma size or pyknotic nuclei count were detected in any of the samples 48 h after transfection (data not shown). An inverse relationship between Pp2a activity and Anp32a levels was noted in the cerebellum and in a retinoic acid differentiated human SH-SY5Y neuronal cell model of SCA1, and Anp32a co-expression restored GSK3b ser-9 phosphorylation levels. Therefore, we investigated whether increasing ANP32A levels in the ATXN1[80Q] expressing SH-SY5Y cells by co-transfection had any effect on the neurite morphology alterations (Fig. 4, Supplementary  Material Fig. S6 (Fig. 4A-C) . That increasing the expression of the PP2A inhibitor ANP32A induces an increase in levels of the activity inhibitory phosphosite GSK3b ser9 suggests that ANP32A regulates its dephosphorylation. Interestingly, both GSK3b and ANP32A have been shown to exert differential effects on neurite formation, extension and stability, as well as spine density (17, 18, 33) . These data suggest that GSK3b activity is increased in the SCA1 mouse model (B05) but not in the WT ATXN1 overexpressing (A02) mice due to the mutant ATXN1-mediated modulation of Pp2a holoenzyme composition in addition to its effect on the expression of the inhibitor Anp32a. Furthermore, the expression of Anp32a was sufficient to increase GSK3b phosphorylation levels at serine-9 which would then lower its activity. In agreement with our results, lithium, an inhibitor of GSK3b activity, was found to ameliorate SCA1 motor deficits (4).
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DISCUSSION
The aim of this study was to determine whether ataxin-1, in addition to being a substrate for Pp2a in the nucleus as has been recently reported (38) , also has a regulatory role on Pp2a activity and whether the expanded polyglutamine within ataxin-1 modulates these effects. Based on the strong inhibition exerted by Anp32a on Pp2a activity and our previous evidence showing that mutant ataxin-1 containing the polyglutamine-expansion interacted strongly with Anp32a/Lanp in cells (14, 16, 40) , we hypothesized that mutant ataxin-1 may exert a regulatory effect on Pp2a activity in the mouse cerebellum. Indeed this was the case since we found that ataxin-1 has a significant effect on Pp2a activity in the mouse cerebellum; however, it had a more significant and broader effect on Pp2a than we anticipated. Here, we also found that Atxn1 regulates the expression of at least two important modulators of Pp2a substrate specificity and activity: the bb regulatory subunit and the endogenous Pp2a inhibitor, Anp32a also known as Lanp/I1PP2A/PHAPI/ pp32/mapmodulin. We show that the Pp2a in the cerebellum from mice lacking Atxn1 has significantly less activity than in wild-type mice, whiereas the Pp2a from mice overexpressing wild-type ATXN1 (A02) is more active. In the SCA1 B05 mice expressing the polyglutamine-expanded mutant form of human ataxin-1, Pp2a activity is induced by almost 3-fold. Therefore, the polyglutamine mutation appears to enhance the ataxin-1-mediated positive regulation of Pp2a activity. Analysis of the components of the Pp2a holoenzyme revealed that the Pp2a catalytic subunit shows lower levels of phosphorylated Y307 only in the SCA1 mice expressing mutant ATXN1. It has been previously shown that Y307 phosphorylation inhibits the Pp2a-b regulatory subunits binding to the catalytic-scaffold dimer (24) so that the decreased phosphorylation of the Pp2a-c in the SCA1 mice may allow for a wider range of regulatory subunit binding to the core enzyme dimer thereby contributing to the enhanced Pp2a activation detected. Src-family kinases are known to phosphorylate the Y307 site in the Pp2a-c; however, the nature of modulators of these kinases in the cerebellum is not clear (22) . Interestingly, VEGF an angiogenic factor with neurotrophic effects, which has been implicated and found to ameliorate pathogenesis in SCA1, activates src-family kinases and thus could also have inhibitory effects on Pp2a through Y307 phosphorylation thereby potentially normalizing the Pp2a activity levels in the SCA1 mice (41, 42) . Furthermore, the analysis of the Atxn1-mediated changes in the Pp2a holoenzyme components also revealed that Atxn1 regulates the expression of the Pp2a-bb2 regulatory subunit and its endogenous inhibitor, Anp32a. While Atxn1 induces the expression of bb2 it down-regulates the expression of Anp32a in the cerebellum. However, the mutation within Atxn1 appears to enhance the Anp32a down-regulating effect since the SCA1 mouse (B05) has 30 copies of the transgene while the A02 mouse is known to have at least three times more (43) and the effects on Anp32a levels are not significantly different in both strains. In contrast, the mutant Atxn1 appears to lose its ability to induce the expression of Pp2a-bb2. These effects were also seen in the cell culture model, where the same amount of plasmid was transfected for both wild-type and mutant ATXN1. Likewise, this resembles the effects we previously observed with the ataxin-1 mutation on the Drd2 gene promoter (9) . Anp32a, albeit widely distributed in the brain, is highly expressed in brain regions affected in SCA1 such as the cerebellum, motor cortex and brainstem (15) . It is known to selectively inhibit Pp2a activity by binding the catalytic subunit (16) . Therefore increased levels of Anp32a and its binding to Pp2a-c in the Atxn1 KO mice are expected to induce decreased Pp2a activity while the opposite is true in the cerebellum of the A02 and the SCA1 B05 mice where Anp32a levels are lower than in wildtype mice. The Pp2a regulatory subunit bb2 has been shown to be highly and selectively expressed in PCs in the cerebellum (25) . It is expressed as two isoforms bb1 and bb2, both being present in the cytoplasm and the bb2 being able to translocate to the mitochondria where it plays a role in its fusion -fission cycles. It is noteworthy to mention that another spinocerebellar ataxia, SCA12, which like SCA1 is characterized by the loss of cerebellar PCs, is caused by a CAG expansion within the promoter of the Bb1 gene and in vitro studies suggest that this mutation could induce up-regulation of Bb1 expression (26, 27) . However, the specific effect of the mutation in SCA12 and how it may affect the expression of the other isoform, bb2, is unknown. Here, we found that the Atxn1-induced changes in bb2 and Anp32a are at the transcriptional level as demonstrated by changes in their respective mRNAs mirroring the protein levels. Interestingly, our data show that Atxn1 occupies both the Anp32a and bb2 promoters leading us to propose that Atxn1 regulates Anp32a as part of an inhibitory transcription complex and in contrast it is also able to bind to an activating transcriptional complex regulating the Ppp2r2b2 and other genes including Drd2 as we have previously shown (9) .
In addition to transcriptional regulation, analysis of the Pp2a holoenzyme also revealed that another Pp2a regulatory subunit, b ′ d is post-translationally regulated in both the Atxn1 KO and SCA1 mice, suggesting it may be due to the loss of function of mutant Atxn1 on Drd2 expression (9, 35) . We previously showed that Atxn1 activates the expression of Drd2 and that the mutation within Atxn1 compromises this function (9) . The b ′ d subunit is phosphorylated by PKA and this phosphorylation has been shown to increase the PP2a-b ′ d holoenzyme activity (34) . PKA activity is known to be suppressed during Drd2-mediated signalling, thus the decrease in Drd2 in the cerebellum in both the Atxn1 KO and SCA1 mice may dysregulate PKA activation (35) . We propose that this increase in PKA activity may thus result in the increased levels of the phosphorylated b ′ d protein in both, the Atxn1 KO and SCA1 B05 mice. Overall, our results point to an alteration not only in the levels of Pp2a activity in the cytoplasmic fractions from the SCA1 B05 mice, but also in the composition of the holoenzyme, with less inhibitory regulation by Anp32a, and less bb2 but more active b ′ d regulatory subunit bound holoenzyme. In addition, there are proportionately more b-type regulatory subunit containing Pp2a holoenzymes since there are lower levels of the b-type subunitbinding inhibitory phosphosite Y307 on the catalytic subunit in the SCA1 mice (B05). All of these account for the higher overall Pp2a activity in the SCA1 with distinct Pp2a holoenzyme specificity than the A02 or WT mice. The proposed model and summary of the findings is shown in Figure 5 .
Alterations in Pp2a regulated pathways, specifically Erk2 and Gsk3b were identified by the quantification of phosphosite levels known to modulate their respective activation state. Gsk3b phosphorylation in ser9, indicative of inactive enzymatic activity, is found increased in the cerebellum of the Atxn1 KO mice while the mutant ATXN1 over-expressing mice and cells show lower phospho-ser9 in GSK3b suggesting its enhanced activation. Likewise at the Thr202/Tyr204, indicative of activation, is increased in fractions from the cerebellum of Atxn1 KO mice and slightly decreased in the SCA1 mice (B05). That Figure 5 . The proposed model of the ataxin-1 induced alterations of Pp2a activity and holoenzyme composition in the cerebellum of 5-week-old mice. Wild-type ataxin-1 induces the expression of the Pp2a-bb2 protein from the Ppp2r2bb2 gene. In addition, it suppresses the expression of Anp32a resulting in active Pp2a catalytic subunits, enriched in the Y307 phosphosite, which inhibits its binding to b-type Pp2a regulatory subunits. We previously showed that Atxn1 regulates the expression of Drd2 (9), a negative regulator of PKA which is known to phosphorylate the Pp2a regulatory subunit b ′ d at the activation inducing phosphosite S566. On the other hand, the mutant Atxn1 is unable to induce either the expression of the Ppp2r2b2 or Drd2 genes (loss of function), exerts an enhanced suppression of Anp32a (gain of function) and induces a decrease in Y307 phophosite (gain of function) on the Pp2a catalytic subunit. Therefore, the mutant Atxn1 expressing neurons would have more Pp2a holoenzymes with b-type regulatory subunits of which a low proportion would be of the bb2 type and a higher level of more active b ′ d containing Pp2a holoenzymes than wild-type Atxn1-expressing neurons.
the Erk2 signalling pathway is regulated by Pp2a has been demonstrated in the Pp2a-ca dominant negative (L199P) Pp2a transgenic mice, a Pp2a-b ′ b and Pp2a-b knockdown cell culture and drosophila genetic model (29, 39, 44, 45) . In contrast, the Pp2a-b ′ d null mouse shows alterations on the Gsk3b but not in Erk2 activation (30) . Interestingly, in the Pp2a-b ′ d null mice the Gsk3b activation was found altered in the cortex and other brain regions but not in the cerebellum (30) , suggesting some functional redundancy in the cerebellum. Therefore, the activation of the Pp2a-b
′ d holoenzyme appears to be tightly regulated, thus pointing to an important role in the mouse cerebellum.
The PP2A B ′ d and B ′ b have been shown to regulate the TrkA-mediated neurite growth (32, 46) . Furthermore, GSK3b has been shown to mediate the trkA-induced neurite growth through MAP1B phosphorylation (33) . Interestingly, while Anp32a appears to inhibit neurite formation in NGF-treated PC12 cells (17) , it was shown to promote MAP1B-induced neurite extension in differentiated mouse neuronal cell line neuro2a (18) . These seemingly contradictory results have been previously described as GSK3b appears to have distinct roles in neurite formation, extension and stabilization, with high GSK3b activity favouring neurite formation, whereas low activity favouring neurite extension or stability in differentiated neuronal cells (33, 47) . Interestingly, both the wild-type (A02) and mutant ATXN1 mice overexpressing mice (B05) had low Anp32a levels, but only the B05 mice showed reduced phospho-GSK3b or phospho-Erk2 levels. This suggests that Anp32a levels are not sufficient to account for the alteration and consequent activation of GSK3b and decreased Erk2 activity. The same was observed in the SH-SY5Y SCA1 cell model. These data then highlight the role for the alterations in the regulatory subunit-specific Pp2a holoenzymes by the mutant ataxin-1 and suggests that the specific active Pp2a holoenzyme(s) involved in dephosphorylation of ser9 in GSK3b is enriched in the mutant ataxin-1-expressing mice or cell model. Therefore, we reasoned that because Anp32a inhibits Pp2a by binding to the catalytic subunit and Anp32a is down-regulated in the cerebellum of the SCA1 mice and in mutant ATXN1 expressing differentiated SH-SY5Y cells, restoring Anp32a levels may increase GSK3b phosphorylation levels thus decreasing its activity and preventing the abnormal neuritic morphology induced by the expression of the mutant ATXN1. Indeed, this was the case, we found that the neurite length shortening and spine loss were ameliorated in ATXN1[80Q] expressing SH-SY5Y cells co-transfected with Anp32a. That co-expression of Anp32a was able to increase GSK3b phosphorylation levels in both the WT and mutant ATXN1 expressing SH-SY5Y cells shows that there appears to be no alterations in the GSK3b phosphorylating kinase in either, but rather that the mutant ATXN1 has an effect on the GSK3b dephosphorylation. Therefore, taken together these studies point to different potential targets of therapeutic intervention related to the altered Pp2a activity in SCA1, namely the Y307 Pp2a-c phosphorylation, phospho-Pp2a-b ′ d and the Pp2a-bb2 holoenzyme levels and the increased GSK3b activity. The latter, has been previously explored since lithium, was found to ameliorate to some degree the motor deficits in the SCA1 B05 mouse model (4) . We propose that using a more specific compound inhibitor of GSK3b or modulators of the other targets mentioned above may serve to restore some of the signalling pathways and functionality altered in Purkinje neurons of SCA1 patients. Interestingly, dysregulation of PP2A and GSK3b has also been found in other neurodegenerative disorders such as Alzheimer's disease where genetic linkage data have suggested ATXN1 as a risk factor in some patients (48) .
In conclusion, this study assigns a new biological function onto ataxin-1: the regulation of Pp2a activity and its components, specifically the regulatory subunit Ppp2r2b isoform 2 (bb2) and the Pp2a endogenous inhibitor Anp32a, both of which are highly enriched in cerebellar PCs. In addition, ataxin-1 was found to regulate the inhibiting Y307 phosphosite in Pp2a-c and levels of the activating S566 phosphosite in the Pp2a regulatory subunit Pp2a-b
′ d. We demonstrate that these functions of Atxn1 are dysregulated in the polyglutamineexpanded mutant ataxin-1 in SCA1 neuronal cell lines and SCA1 transgenic mice. Our results point to the dysregulation of this newly assigned function of ataxin-1 in the cerebellar neurodegeneration of SCA1 and uncovers new possible targets for therapy.
MATERIALS AND METHODS
Mice
Five-week-old inbred Atxn1-null (Sca1 KO 2/2 ) and transgenic mice carrying the mutant SCA1 allele with 82 CAG repeats (B05) or an interrupted wild-type SCA1 allele with 30 repeats (A02) driving the expression in cerebellar PCs of mutant or wildtype Ataxin-1 containing 82 or 30 glutamines, respectively, were previously described (43, 49) . The SCA1 mice and respective controls (B05, A02 and FVB/NJ WT) were provided by Dr Massimo Pandolfo (Institute of Neuroscience, Université Libre de Bruxelles, Belgium). All animal procedures were carried out in accordance with EU and local regulations and approved by the appropriate Ethics Committees.
Protein sample preparations and immunoblotting
Proteins from mouse cerebella or cultured cells were extracted by homogenization in hypotonic lysis buffer: 10 mM Hepes, 10 mM KCl, 2 mM EGTA, 320 mM sucrose, 5 mM MgCl 2 , 1 mM DTT, 25 mM NaF, 2.5 mM NaVO 3 and protein inhibitor cocktail (Roche). Hypotonic lysis fractions were generated by differential centrifugation at 48C. Briefly, cerebellar tissue or cell pellets were dounced homogenized with hypotonic buffer (35 mg of tissue/ml of buffer) and incubated on ice for 15 min. After centrifugation at 500g for 10 min to yield S1 and P1 fractions the supernatant was centrifuged again to remove residual nuclei. The remaining S1 fraction was centrifuged at 900g for 10 min to yield the S2 fraction used as cytoplasmic fractions in these studies. Residual membranes were extracted from the P1 fraction with 0.1% triton in hypotonic buffer after centrifugation at 500g for 10 min to yield the nuclear pellet. We extracted the nuclei with 1% triton in hypotonic buffer, 10 min to obtain the nuclear triton soluble (NS) and insoluble fractions (N). Protein samples were mixed with 2× SDS-sample buffer (625 mm Tris, pH 6.8, 10% SDS, 50% glycerol, 1 mM DTT and bromophenol blue) and separated by electrophoresis before transfer to PVDF membranes (Life . Infrared-dye conjugated secondary antibodies (Li-Cor Biosciences) were detected using the Odyssey analyzer (Li-Cor Biosciences). Immunoblot images were quantified using the software v2-1 (Li-Cor Biosciences). Statistical analyses were performed using the SSPS statistical software with significance set at P , 0.05.
Immunoprecipitations
Hypotonic lysates were brought to 0.1% triton and fresh protease inhibitors were added (Roche) prior to clearing with 50 ml of magnetic protein A/G beads (LSKMAGA02 and LSKMAGG08, Merck-Millipore). The protein was incubated overnight with 4 ml of antibody, PP2A-C mouse mAb ID6 (05-421, Merck-Millipore, rabbit polyclonal PP2A-C or PP2A-A antibodies (2038, Cell Signaling technology and 05-577, Merck-Millipore) prior to incubation with protein A/G magnetic beads and the immunoprecipitates analysed by immunoblotting. Sixty micrograms of protein were used for Pp2a activity assays and 250 mg for analytical immunoprecipitations.
PP2A activity assays
We used a phosphatase activity assay for measuring the PP2A activity in tissue extracts. The procedures of sample preparation, immunoprecipitation and substrate incubation were performed according to the manufacturer's protocol (17-313, MerckMillipore). Briefly, Pp2a-c was immunoprecipitated from 60 mg of pre-cleared protein extract with ID6 Pp2a-c antibody and the precipitate was incubated with a synthetic phosphorylated peptide for 10 min. The colour development of liberated phosphate was performed in 96-well plastic-Falcon plates and the absorbance (630 nm) was measured using the Varioskan plate reader (Thermo Scientific). Linearity of the test was confirmed in a range of 40-100 mg protein used for the initial immunoprecipitation. Liberated phosphate was read off from a standard curve (0 -1000 pmol phosphate in 125 ml) and specific activity was expressed as: liberated phosphate in picomole/relative levels of Pp2a-c. (17) or empty vector plasmid in addition to EGFP into SH-SY5Y cells grown in DMEM medium containing 10% FBS (Sigma), 2 mM glutamine, 50 mg/ml Penicillin/Streptomycin (Life technologies) at 70% confluence in 10 cM culture dishes using Lipofectamine 2000 (Life technologies) and OptiMEM medium (Life technologies) according to the manufacturer's instructions. Four hours after transfection, the culture medium was replaced with SH-SY5Y culture medium B: Neurobasal, B27 supplement, 10 mM retinoic acid, 2 mM glutamine, 50 mg/ml Penicillin/Streptomycin. Forty-eight hours after medium change cells were harvested for protein preparations or fixed with 2% paraformaldehyde for morphology assessment or immunofluorescence. Transfection efficiency was 60%. For immunofluorescence fixed transfected cells were permeabilized with 0.1% triton in PBS for 1 h and following washing and blocking with 5% goat serum in PBS for 30 min cells were incubated with antibody to phospho-GSK3b (ser9) in PBS with 1% goat serum. Immunoreactivity was detected with texas red antibody to mouse IgG and visualized using a Zeiss AxioObserver Z1 inverted Microscope (Zeiss).
Neuritic morphology assessment
Neurite length (two or more soma sizes) and neurites with spines in at least half their length were analysed using the Axiovision software (Zeiss). EGFP positive cells were analysed in four to six random areas within four wells (200 -550 cells) for each transfected sample. Experiments were done in duplicate with similar results.
Quantitative RT -PCR
qRT-PCR was performed to test levels of gene expression in four to seven WT and four to seven ataxin-1 KO mice cerebellum, hippocampus and striatum samples. We performed a single step reverse transcriptase PCR reaction (Qiagen) with 7900 HT fast real-time PCR system (Applied Biosystems), continuous fluorescence detection and SYBR green fluorescence reagents as specified by the manufacturer in a final reaction volume of 20 ml. Primer sequences were designed for each target gene containing minimal internal structures (i.e. hairpins and primer dimers) and optimal melting temperatures with each Tm within 18C of the other using PrimerEXpress (Appled Biosystems) to target splice sites within the RNA sequence. The primer sequences are described in Supplementary Material, Table S1 . Samples were compared using the relative comparative CT method (51) . Each primer was used at a final concentration of 0.1 mM and the qRT-PCR conditions are as follows: 958C for 30 s, and 40 cycles of 958C for 5 s, 628C for 20 s, 728C for 15 s.
Chromatin immunoprecipitation
SH-SY5Y cells were cultured in 100 cM plates as mentioned above and transfected with 4 mg of Flag-tagged ATXN1[30Q], ATXN1[80Q] or empty vector as described earlier (9) . Forty-eight hours after transfection, cells were fixed with 1% paraformaldehyde and further processed for ChIP analysis. Immunoprecipitations were carried out using 4 mg of antibody to flag (M2, Sigma) or control serum. Input and immunoprecipitated DNAs were subjected to PCR amplification with the primers listed in Supplementary Material, Table S2 . For in vivo ChIP assays, whole cerebella from 5-week-old WT and KO mice were dissected out and cut into 50 mg pieces. Cerebellar tissues were washed with ice-cold PBS containing protease inhibitors (PBS/Pi), resuspended in PBS/Pi containing 1% formaldehyde, incubated at room temperature for 15 min, centrifuged at 3000g and washed with PBS/Pi. Further processing of the cells and cerebellar samples was done using the Magna ChIP Kit components (16-663, Merck-Millipore) as previously described (9), using the primers listed in the Supplementary Material, Table S2 . PCR amplifications were performed with two DNA input volumes and conditions chosen that did not saturate the PCR reaction. Briefly, chromatin extracts from three cerebellar WT and KO samples were amplified independently in parallel using two DNA amounts as input in the PCR reaction (1 and 2 ml). The Transcriptional Regulatory Element Database (TRED, http://rulai.cshl. edu/TRED) was searched to obtain the promoter sequences of the genes in this study. The retrieved predicted promoter regions were further analysed by aligning the putative open reading frames with ClustalW2 (52). Retrieved sequences were subsequently analysed with ConSite to obtain DNA-binding profiles for Sp1, HBP1 and RA/thyroid hormone nuclear receptors as in Goold et al. (9) . Primers used for ChIP experiments are listed in Supplementary Material, Table S2 . Manual hotstart was done at 958C for 2 min prior to Taq addition, followed by 958C for 5 min, and 40 cycles: 958C for 30 s, 588C for 60 s and 728C for 40 s; 0.1 mM of each primer, 5% dimethyl sulfoxide, 2% formamide and 0.2 ml Ecotaq (Bioline, UK) were used per each reaction.
Statistics
Statistical data were analysed with SPSS 21.0 (IBM corp). Data were tested for normal distribution and equality of variances using Shapiro-Wilks' W-test and Levene's test of homogeneity of variances, respectively. Normally distributed data were analysed by one-way ANOVA followed by post hoc comparisons with either the Tukey HSD (honestly significant difference test) for groups of data with equal variances or, alternatively, with the Games -Howell test in one-way ANOVA analyses with unequal variances. Statistical significance was defined as a P-value , 0.05. (SEM denotes for standard error of the mean.) 
